title: Regulation of thrombopoietin levels by c-mpl-mediated binding to platelets.
abstract: The involvement of platelets and the c-mpl receptor in the regulation of thrombopoietin (TPO) plasma concentrations and tissue mRNA levels was investigated in both normal mice and mice defective in c-mpl (c-mpl-/-). Although c-mpl-/- mice have fewer platelets and higher plasma TPO activity than normal mice, there was no increase in TPO mRNA levels as measured by an S1 nuclease protection assay. After the intravenous injection of 125I-TPO, specific uptake of radioactivity by the spleen and blood cells was present in the normal mice, but absent in the c-mpl-/- mice. Platelet-rich plasma (PRP) from normal mice was able to bind and internalize 125I-TPO, whereas PRP from c-mpl-/- mice lacked this ability. Analysis of 125I-TPO binding to normal PRP indicated that binding was specific and saturable, with an approximate affinity of 560 pmol/L and 220 receptors per platelet. PRP from normal mice was also able to degrade 125I-TPO into lower molecular weight fragments. After the intravenous injections, c-mpl-/- mice cleared a dose of 125I-TPO at a much slower rate than did normal mice. Injection of washed platelets from normal mice into c-mpl-/- mice resulted in a dramatic, but transient, decrease in plasma TPO levels. These data provide evidence that platelets regulate plasma TPO levels via binding to the c-mpl receptor on circulating platelets.
authors.affiliation: Departments of Molecular Oncology, Genentech Inc, South San Francisco, CA USA.
authors.forename: P J
authors.initials: PJ
authors.lastname: Fielder
authors.forename: A L
authors.initials: AL
authors.lastname: Gurney
authors.forename: E
authors.initials: E
authors.lastname: Stefanich
authors.forename: M
authors.initials: M
authors.lastname: Marian
authors.forename: M W
authors.initials: MW
authors.lastname: Moore
authors.forename: K
authors.initials: K
authors.lastname: Carver-Moore
authors.forename: F J
authors.initials: FJ
authors.lastname: de Sauvage
mesh_terms: D000818:Animals; D001483:Base Sequence; D001773:Blood Cells / Q000378:metabolism; D001792:Blood Platelets / Q000378:metabolism*; D005786:Gene Expression Regulation / Q000502:physiology*; D006207:Half-Life; D006801:Humans; D008297:Male; D008657:Metabolic Clearance Rate; D051379:Mice; D008810:Mice, Inbred C57BL; D008817:Mice, Mutant Strains; D008969:Molecular Sequence Data; D009363:Neoplasm Proteins; D017713:Platelet Transfusion; D011485:Protein Binding; D011518:Proto-Oncogene Proteins / Q000378:metabolism*; D012333:RNA, Messenger / Q000096:biosynthesis / Q000235:genetics; D018121:Receptors, Cytokine; D053628:Receptors, Thrombopoietin; D011994:Recombinant Proteins / Q000493:pharmacokinetics; D013154:Spleen / Q000378:metabolism; D013926:Thrombopoietin / Q000096:biosynthesis / Q000097:blood* / Q000235:genetics / Q000493:pharmacokinetics; D014018:Tissue Distribution
chemical_list: D009363:Neoplasm Proteins; D011518:Proto-Oncogene Proteins; D012333:RNA, Messenger; D018121:Receptors, Cytokine; D053628:Receptors, Thrombopoietin; D011994:Recombinant Proteins; C082218:MPL protein, human; D013926:Thrombopoietin